The Biopharmaceutical Industry is Currently Developing Nearly 600 Pediatric Medicines

18 February 2020

GMP News

America’s biopharmaceutical researchers are committed to studying, developing and testing medicines to meet the unique needs of pediatric patients. New treatment options for infants, children and adolescents can be complex and often require different clinical approaches than adult treatment pathways. According to a new report released, there are nearly 600 pediatric medicines currently in development.

There are more than 2,100 industry-sponsored pediatric clinical trials underway, testing 580 investigational medicines and involving more than 1.2 million pediatric patients across a variety of therapeutic areas, including diseases where there is significant unmet medical need. Medicines in development include:

Researchers are also testing medicines approved for use in adults to determine safe and effective dosage levels for children. Current investigations include:

The Best Pharmaceuticals for Children Act (BPCA) and Pediatric Research Equity Act (PREA) work together to foster pediatric drug development. These acts were permanently reauthorized in 2012, and create a balanced approach that generates important safety and efficacy information on use of medicines in children and enables biopharmaceutical companies to continue to make significant investments in pediatric drug research.

Source

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more